 | |
| Names | |
|---|---|
| Other names Antrin; Lu texaphyrin; Lu-Tex; Lutetium texaphyrin; Lutrin; Optrin; PCI 0123 | |
| Identifiers | |
3D model (JSmol) | |
| ChemSpider | |
| DrugBank | |
| UNII | |
| |
| |
| Properties | |
| C52H72LuN5O14 | |
| Molar mass | 1166.136 g·mol−1 |
Except where otherwise noted, data are given for materials in theirstandard state (at 25 °C [77 °F], 100 kPa). | |
Motexafin lutetium is atexaphyrin, marketed asAntrin by Pharmacyclics Inc.
It is a photosensitiser for use inphotodynamic therapy to treat skin conditions and superficial cancers.
It has also been tested for use inphotoangioplasty (photodynamic treatment of diseased arteries).[1]
It is photoactivated by 732 nm light which allows greater depth of penetration.[2]
Phase II clinical trials were in progress in 1999.[3]
A phase I trial forprostate cancer reported in 2009.[4]
 | Thisdermatologicdrug article is astub. You can help Wikipedia byexpanding it. |
